Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients
To evaluate the value of the aspartate aminotransferase-to-platelet ratio index (APRI) for hepatocellular carcinoma (HCC) patients who underwent transarterial chemoembolisation (TACE). A total of 315 patients were enrolled, who were randomly divided into the training cohort (n=158) and the validatio...
Gespeichert in:
| Veröffentlicht in: | Clinical radiology 2018-03, Vol.73 (3), p.259-265 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 265 |
|---|---|
| container_issue | 3 |
| container_start_page | 259 |
| container_title | Clinical radiology |
| container_volume | 73 |
| creator | Tang, T. Qiu, J.-L. Li, G.-W. Huang, M.-P. Li, Y. Li, Y.-J. Gu, S.-Z. |
| description | To evaluate the value of the aspartate aminotransferase-to-platelet ratio index (APRI) for hepatocellular carcinoma (HCC) patients who underwent transarterial chemoembolisation (TACE).
A total of 315 patients were enrolled, who were randomly divided into the training cohort (n=158) and the validation cohort (n=157). The optimal cut-off value of the APRI was determined using the X-tile software in the training cohort, and was validated in the validation cohort. Several serum-based markers, neutrophil-to-lymphocyte (N/L) and aspartate aminotransferase-to-alanine aminotransferase (AST/ALT) ratios were included to compare with the APRI. To predict individual survival rate, independent predictors were included to build a nomogram.
Using the X-tile, a cut-off value of the APRI as 0.40 was yielded to distinguish patients with distinct outcomes in the training cohort, but failed for the N/L and ALT/AST ratios. In the training cohort, 66 patients with high APRI had poorer survival (p |
| doi_str_mv | 10.1016/j.crad.2017.09.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1951570460</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0009926017304634</els_id><sourcerecordid>1951570460</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-9d27e5d918d286b5080bc5ee3e8c35c1b48cd7a9acb13503b9777ed4c6f80dd83</originalsourceid><addsrcrecordid>eNp9UctuFDEQtBAR2QR-gAPykcsMbc_TEpcoSiBSJC5E4mZ57F7i1Yw9uL1I_AcfHA8bOHJy211V3a5i7K2AWoDoPxxqm4yrJYihBlUDtC_YTjR9V0mpvr1kOwBQlZI9nLMLosN2bWX7ip1LBY0s9Y79vqLVpGwycrP4EHMygfaYDGGVY7XOpTNj5slkH_ma0HmbiSekNQZCniP_QykamLyZuX3EJeIyxdnTxgncBFeI8XuI5In7wB9xNTlanOfjbBK3JtkyeTG8PHsMmV6zs72ZCd88n5fs4fbm6_Xn6v7Lp7vrq_vKNl2fK-XkgJ1TYnRy7KcORphsh9jgWABWTO1o3WCUsZNoOmgmNQwDutb2-xGcG5tL9v6kW9b7cUTKevG07WUCxiNpoTrRDdD2UKDyBLUpEiXc6zX5xaRfWoDe0tAHvaWhtzQ0KF3SKKR3z_rHaUH3j_LX_gL4eAJg-eVPj0mTLQ7Y4nJCm7WL_n_6T45FoSA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1951570460</pqid></control><display><type>article</type><title>Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Tang, T. ; Qiu, J.-L. ; Li, G.-W. ; Huang, M.-P. ; Li, Y. ; Li, Y.-J. ; Gu, S.-Z.</creator><creatorcontrib>Tang, T. ; Qiu, J.-L. ; Li, G.-W. ; Huang, M.-P. ; Li, Y. ; Li, Y.-J. ; Gu, S.-Z.</creatorcontrib><description>To evaluate the value of the aspartate aminotransferase-to-platelet ratio index (APRI) for hepatocellular carcinoma (HCC) patients who underwent transarterial chemoembolisation (TACE).
A total of 315 patients were enrolled, who were randomly divided into the training cohort (n=158) and the validation cohort (n=157). The optimal cut-off value of the APRI was determined using the X-tile software in the training cohort, and was validated in the validation cohort. Several serum-based markers, neutrophil-to-lymphocyte (N/L) and aspartate aminotransferase-to-alanine aminotransferase (AST/ALT) ratios were included to compare with the APRI. To predict individual survival rate, independent predictors were included to build a nomogram.
Using the X-tile, a cut-off value of the APRI as 0.40 was yielded to distinguish patients with distinct outcomes in the training cohort, but failed for the N/L and ALT/AST ratios. In the training cohort, 66 patients with high APRI had poorer survival (p<0.001) than did 92 patients with low APRI. Using the same cut-off value of APRI, 61 patients with high APRI had poorer survival (p<0.001) than did 96 patients with low APRI in the validation cohort. Furthermore, a nomogram, including the APRI, TACE cycles, tumour size, and tumour number, was built based on the training cohort, and validated well in the validation cohort (concordance index [C-index] 0.713).
The APRI is a promising marker to predict treatment response and outcome for HCC patients after TACE treatment.
•The APRI is superior to the N/L, AST/ALT ratios in predicting survival for HCC patient after TACE treatment.•The APRI is a serum-based marker to predict TACE response before treatment administrated.•The nomogram, including the APRI, is a valid tool to predict individual patient’s survival in clinical routine.</description><identifier>ISSN: 0009-9260</identifier><identifier>EISSN: 1365-229X</identifier><identifier>DOI: 10.1016/j.crad.2017.09.004</identifier><identifier>PMID: 29032942</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Alanine Transaminase - blood ; Antineoplastic Agents - administration & dosage ; Aspartate Aminotransferases - blood ; Biomarkers, Tumor - blood ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - diagnostic imaging ; Carcinoma, Hepatocellular - therapy ; Chemoembolization, Therapeutic - methods ; Ethiodized Oil - administration & dosage ; Female ; Fluoroscopy ; Humans ; Liver Neoplasms - blood ; Liver Neoplasms - diagnostic imaging ; Liver Neoplasms - therapy ; Male ; Middle Aged ; Platelet Count ; Predictive Value of Tests ; Prognosis ; Software ; Survival Analysis ; Treatment Outcome</subject><ispartof>Clinical radiology, 2018-03, Vol.73 (3), p.259-265</ispartof><rights>2017 The Royal College of Radiologists</rights><rights>Copyright © 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-9d27e5d918d286b5080bc5ee3e8c35c1b48cd7a9acb13503b9777ed4c6f80dd83</citedby><cites>FETCH-LOGICAL-c356t-9d27e5d918d286b5080bc5ee3e8c35c1b48cd7a9acb13503b9777ed4c6f80dd83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.crad.2017.09.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29032942$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tang, T.</creatorcontrib><creatorcontrib>Qiu, J.-L.</creatorcontrib><creatorcontrib>Li, G.-W.</creatorcontrib><creatorcontrib>Huang, M.-P.</creatorcontrib><creatorcontrib>Li, Y.</creatorcontrib><creatorcontrib>Li, Y.-J.</creatorcontrib><creatorcontrib>Gu, S.-Z.</creatorcontrib><title>Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients</title><title>Clinical radiology</title><addtitle>Clin Radiol</addtitle><description>To evaluate the value of the aspartate aminotransferase-to-platelet ratio index (APRI) for hepatocellular carcinoma (HCC) patients who underwent transarterial chemoembolisation (TACE).
A total of 315 patients were enrolled, who were randomly divided into the training cohort (n=158) and the validation cohort (n=157). The optimal cut-off value of the APRI was determined using the X-tile software in the training cohort, and was validated in the validation cohort. Several serum-based markers, neutrophil-to-lymphocyte (N/L) and aspartate aminotransferase-to-alanine aminotransferase (AST/ALT) ratios were included to compare with the APRI. To predict individual survival rate, independent predictors were included to build a nomogram.
Using the X-tile, a cut-off value of the APRI as 0.40 was yielded to distinguish patients with distinct outcomes in the training cohort, but failed for the N/L and ALT/AST ratios. In the training cohort, 66 patients with high APRI had poorer survival (p<0.001) than did 92 patients with low APRI. Using the same cut-off value of APRI, 61 patients with high APRI had poorer survival (p<0.001) than did 96 patients with low APRI in the validation cohort. Furthermore, a nomogram, including the APRI, TACE cycles, tumour size, and tumour number, was built based on the training cohort, and validated well in the validation cohort (concordance index [C-index] 0.713).
The APRI is a promising marker to predict treatment response and outcome for HCC patients after TACE treatment.
•The APRI is superior to the N/L, AST/ALT ratios in predicting survival for HCC patient after TACE treatment.•The APRI is a serum-based marker to predict TACE response before treatment administrated.•The nomogram, including the APRI, is a valid tool to predict individual patient’s survival in clinical routine.</description><subject>Adult</subject><subject>Aged</subject><subject>Alanine Transaminase - blood</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Aspartate Aminotransferases - blood</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - diagnostic imaging</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Chemoembolization, Therapeutic - methods</subject><subject>Ethiodized Oil - administration & dosage</subject><subject>Female</subject><subject>Fluoroscopy</subject><subject>Humans</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - diagnostic imaging</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Platelet Count</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Software</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0009-9260</issn><issn>1365-229X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UctuFDEQtBAR2QR-gAPykcsMbc_TEpcoSiBSJC5E4mZ57F7i1Yw9uL1I_AcfHA8bOHJy211V3a5i7K2AWoDoPxxqm4yrJYihBlUDtC_YTjR9V0mpvr1kOwBQlZI9nLMLosN2bWX7ip1LBY0s9Y79vqLVpGwycrP4EHMygfaYDGGVY7XOpTNj5slkH_ma0HmbiSekNQZCniP_QykamLyZuX3EJeIyxdnTxgncBFeI8XuI5In7wB9xNTlanOfjbBK3JtkyeTG8PHsMmV6zs72ZCd88n5fs4fbm6_Xn6v7Lp7vrq_vKNl2fK-XkgJ1TYnRy7KcORphsh9jgWABWTO1o3WCUsZNoOmgmNQwDutb2-xGcG5tL9v6kW9b7cUTKevG07WUCxiNpoTrRDdD2UKDyBLUpEiXc6zX5xaRfWoDe0tAHvaWhtzQ0KF3SKKR3z_rHaUH3j_LX_gL4eAJg-eVPj0mTLQ7Y4nJCm7WL_n_6T45FoSA</recordid><startdate>201803</startdate><enddate>201803</enddate><creator>Tang, T.</creator><creator>Qiu, J.-L.</creator><creator>Li, G.-W.</creator><creator>Huang, M.-P.</creator><creator>Li, Y.</creator><creator>Li, Y.-J.</creator><creator>Gu, S.-Z.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201803</creationdate><title>Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients</title><author>Tang, T. ; Qiu, J.-L. ; Li, G.-W. ; Huang, M.-P. ; Li, Y. ; Li, Y.-J. ; Gu, S.-Z.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-9d27e5d918d286b5080bc5ee3e8c35c1b48cd7a9acb13503b9777ed4c6f80dd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alanine Transaminase - blood</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Aspartate Aminotransferases - blood</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - diagnostic imaging</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Chemoembolization, Therapeutic - methods</topic><topic>Ethiodized Oil - administration & dosage</topic><topic>Female</topic><topic>Fluoroscopy</topic><topic>Humans</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - diagnostic imaging</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Platelet Count</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Software</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tang, T.</creatorcontrib><creatorcontrib>Qiu, J.-L.</creatorcontrib><creatorcontrib>Li, G.-W.</creatorcontrib><creatorcontrib>Huang, M.-P.</creatorcontrib><creatorcontrib>Li, Y.</creatorcontrib><creatorcontrib>Li, Y.-J.</creatorcontrib><creatorcontrib>Gu, S.-Z.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tang, T.</au><au>Qiu, J.-L.</au><au>Li, G.-W.</au><au>Huang, M.-P.</au><au>Li, Y.</au><au>Li, Y.-J.</au><au>Gu, S.-Z.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients</atitle><jtitle>Clinical radiology</jtitle><addtitle>Clin Radiol</addtitle><date>2018-03</date><risdate>2018</risdate><volume>73</volume><issue>3</issue><spage>259</spage><epage>265</epage><pages>259-265</pages><issn>0009-9260</issn><eissn>1365-229X</eissn><abstract>To evaluate the value of the aspartate aminotransferase-to-platelet ratio index (APRI) for hepatocellular carcinoma (HCC) patients who underwent transarterial chemoembolisation (TACE).
A total of 315 patients were enrolled, who were randomly divided into the training cohort (n=158) and the validation cohort (n=157). The optimal cut-off value of the APRI was determined using the X-tile software in the training cohort, and was validated in the validation cohort. Several serum-based markers, neutrophil-to-lymphocyte (N/L) and aspartate aminotransferase-to-alanine aminotransferase (AST/ALT) ratios were included to compare with the APRI. To predict individual survival rate, independent predictors were included to build a nomogram.
Using the X-tile, a cut-off value of the APRI as 0.40 was yielded to distinguish patients with distinct outcomes in the training cohort, but failed for the N/L and ALT/AST ratios. In the training cohort, 66 patients with high APRI had poorer survival (p<0.001) than did 92 patients with low APRI. Using the same cut-off value of APRI, 61 patients with high APRI had poorer survival (p<0.001) than did 96 patients with low APRI in the validation cohort. Furthermore, a nomogram, including the APRI, TACE cycles, tumour size, and tumour number, was built based on the training cohort, and validated well in the validation cohort (concordance index [C-index] 0.713).
The APRI is a promising marker to predict treatment response and outcome for HCC patients after TACE treatment.
•The APRI is superior to the N/L, AST/ALT ratios in predicting survival for HCC patient after TACE treatment.•The APRI is a serum-based marker to predict TACE response before treatment administrated.•The nomogram, including the APRI, is a valid tool to predict individual patient’s survival in clinical routine.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29032942</pmid><doi>10.1016/j.crad.2017.09.004</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9260 |
| ispartof | Clinical radiology, 2018-03, Vol.73 (3), p.259-265 |
| issn | 0009-9260 1365-229X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1951570460 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged Alanine Transaminase - blood Antineoplastic Agents - administration & dosage Aspartate Aminotransferases - blood Biomarkers, Tumor - blood Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - diagnostic imaging Carcinoma, Hepatocellular - therapy Chemoembolization, Therapeutic - methods Ethiodized Oil - administration & dosage Female Fluoroscopy Humans Liver Neoplasms - blood Liver Neoplasms - diagnostic imaging Liver Neoplasms - therapy Male Middle Aged Platelet Count Predictive Value of Tests Prognosis Software Survival Analysis Treatment Outcome |
| title | Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A19%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aspartate%20aminotransferase-to-platelet%20ratio%20predicts%20response%20to%20transarterial%20chemoembolisation%20and%20prognosis%20in%20hepatocellular%20carcinoma%20patients&rft.jtitle=Clinical%20radiology&rft.au=Tang,%20T.&rft.date=2018-03&rft.volume=73&rft.issue=3&rft.spage=259&rft.epage=265&rft.pages=259-265&rft.issn=0009-9260&rft.eissn=1365-229X&rft_id=info:doi/10.1016/j.crad.2017.09.004&rft_dat=%3Cproquest_cross%3E1951570460%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1951570460&rft_id=info:pmid/29032942&rft_els_id=S0009926017304634&rfr_iscdi=true |